Résumé
Various arguments support the development of a vaccine targeting human papillomavirus (HPV) for the treatment of HPV-associated head and neck cancer. However, the mucosal localization of this tumor, the HPV-driven downregulation of MHC Class I molecules and various other immunosuppressive mechanisms must be carefully considered to improve the clinical efficacy of such an immunotherapeutic strategy.
langue originale | Anglais |
---|---|
Numéro d'article | e24534 |
journal | OncoImmunology |
Volume | 2 |
Numéro de publication | 6 |
Les DOIs | |
état | Publié - 1 juin 2013 |
Modification externe | Oui |